Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C
Author:
Affiliation:
1. Department of Internal Medicine; University of Michigan Medical Center; Princeton, NJ
2. Bristol-Myers Squibb; Princeton, NJ
3. Department of Pathology; University of Michigan Medical Center; Princeton, NJ
4. Gilead Sciences; Foster City, CA
Publisher
Wiley
Subject
Pharmacology (medical),Transplantation,Immunology and Allergy
Reference24 articles.
1. Hepatitis C virus and liver transplantation;Verna;Clin Liv Dis,2006
2. The association between hepatitis C infection and survival after liver transplantation;Forman;Gastroenterology,2002
3. A longitudinal analysis of hepatitis C virus replication following liver transplantation;Gane;Gastroenterology,1996
4. Systematic review: Anti-viral therapy of recurrent hepatitis C after liver transplantation;Guillouche;Aliment Pharmacol Ther,2011
5. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated Interferon;Levitsky;Gastroenterology,2012
Cited by 133 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. HCV eradication does not protect from fibrosis progression in patients with fibrosing cholestatic hepatitis after liver transplantation;Clinics and Research in Hepatology and Gastroenterology;2022-11
2. Sofosbuvir and daclatasvir are safe and effective in treatment of recurrent hepatitis C virus in Egyptian patients underwent living donor liver transplantation;Egyptian Liver Journal;2020-09-24
3. Efficacy and safety of sofosbuvir-containing regimens in patients with chronic hepatitis C virus infection after liver transplantation: a meta-analysis;Annals of Translational Medicine;2020-05
4. Multivariate Development and Optimization of Stability Indicating Method for Determination of Daclatasvir in Presence of Potential Degradation Products;Chromatographia;2019-08-23
5. Therapy with Direct-Acting Antiviral Agents in Transplanted Patients with HCV Recurrence: A Retrospective Analysis;Hepatitis Monthly;2019-07-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3